Skip to main content

Table 1 Clinical and pathological characteristics of KRAS G12C and non-G12C mutations from the mCohort

From: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

 KRAS G12C (N = 1179)Non-G12C (N = 2819)P-value
Age, mean (range)63 (31–91)62 (14–90)0.02
Sex, n (%)
 Male1005 (85.2%)1899 (67.4%)***
 Female162 (13.7%)875 (31.0%) 
 NA12 (1.0%)45 (1.6%) 
Pathology, n (%)
 Adenocarcinoma1107 (93.9%)2584 (91.7%)#
 Squamous carcinoma23 (2.0%)154 (5.5%) 
 Adeno-squamous carcinoma9 (0.8%)18 (0.6%) 
 LCLC3 (0.3%)13 (0.5%) 
 others37 (3.1%)50 (1.8%) 
Stage, n (%)
 I37 (3.1%)85 (3.0%)0.24
 II38 (3.2%)86 (3.1%) 
 III125 (10.6%)235 (8.3%) 
 IV447 (37.9%)1082 (38.4%) 
 NA532 (45.1%)1331 (47.2%) 
  1. # could not be computed, mCohort lung cancer patients from multiple centers, iCohort lung cancer patients from Guangdong Lung Cancer Institute, NA not available, LCLC large-cell lung cancer